Last reviewed · How we verify
Saxenda
At a glance
| Generic name | Saxenda |
|---|---|
| Also known as | Liraglutide 3mg, GLP-1 analogue, Liraglutide, Victoza, Liraglutide 3.0 |
| Sponsor | Seoul National University Hospital |
| Target | Glucagon-like peptide 1 receptor |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Diabetes mellitus type 2
- Weight loss
Common side effects
- Nausea
- Diarrhea
- Constipation
- Vomiting
- Injection site reactions
- Headache
- Dyspepsia
- Fatigue
- Dizziness
- Abdominal pain
- Increased lipase
- Upper abdominal pain
Key clinical trials
- Preoperative Weight Loss for Open Abdominal Wall Reconstruction (NA)
- RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients. (PHASE4)
- A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia (PHASE2)
- The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
- Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome (PHASE3)
- Effects of GH and Lirglutide on AgRP (PHASE4)
- Pharmacological Treatment - An Overview of Its Role in Managing Childhood Obesity
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Saxenda CI brief — competitive landscape report
- Saxenda updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI